Avacta Group

The company develops cancer therapies using its proprietary pre|CISION drug delivery platform, which utilizes a peptide linker to inactivate existing cancer drugs until they reach the tumor site. These drugs are specifically activated by the FAP enzyme found in tumor-supporting cells, aiming to concentrate the active treatment in the tumor while minimizing systemic toxicity in the bloodstream. The technology is designed to improve the safety and efficacy of established oncology treatments for patients.